Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depsipeptide in Recurrent High-Grade Gliomas
NCT00085540Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of romidepsin in glioma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicities at 4 weeks and Progression-Free Survival at 6 months. Started Jan 2005; status: completed.
02
Drugs
romidepsin
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00085540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085540.